Innovation Pharmaceuticals Inc (IPIX)

[seek the light]

FROM Lilly Report Today:
Today the company is providing an update to its oncology research and development strategy. In addition to building upon new oncology products such as Cyramza (ramucirumab), Lartruvo (olaratumab) and abemaciclib, Lilly will pursue new standard-of-care changing therapies that target tumor dependencies in molecularly enriched populations, build rational combinations that overcome resistance, and develop next-generation immunotherapies. Using this framework, Lilly will now focus on seven pipeline assets for priority internal development and three additional assets which are pending data from ongoing trials. The company has or will seek external partners on the other molecules in clinical development as appropriate.